GenoMethods - Biotechnology, Bioinformatics & AI in Biology

Immix Biopharma eyes FDA filing as NXC-201 posts 89% complete response in AL amyloidosis

NXC-201, Immix Biopharma’s CAR T-cell therapy, hit an 89% complete response rate in relapsed or refractory AL amyloidosis. The company is now moving toward a biologics license application and a focused launch.

By Elena MacLeod · October 4, 2026, 9:24 PM · 5 mins read

Clinical Trials & Evidence

Anixa Biosciences records first three-month stable disease in ovarian cancer CAR-T trial

By Elena MacLeod

Translational Research

FSHR CAR T cell therapy achieves first stable disease in ovarian cancer trial

By Elena MacLeod

Biotechnology News & Analysis

Europe’s biotechnology sector hits a wall on funding and commercialisation

By Adrian Cole

Drug Discovery

Shionogi targets rare disease leadership with $2 billion IntraBio acquisition

By Vivian Lin

IN-DEPTH REPORTING

Biotechnology News & Analysis

Asian Biopharma Giants Reshape Global Dealmaking with Record Transactions

A wave of blockbuster deals from Samsung Biologics, SK Biopharm, and Hanmi Pharmaceutical has pushed South Korea to the front of Asia-Pacific biopharma. Big acquisitions and licensing moves are changing the region’s global standing.

By Vivian Lin · October 4, 2026, 8:52 PM

Bioinformatics Methods & Tools

UNILAG opens hands-on bioinformatics workshop for faculty researchers

October 5, 2026, 6:44 AM

Clinical Trials & Evidence

Oncology teams tackle relapsed CLL with CAR T trials and advanced practice teamwork

October 5, 2026, 6:28 AM

BIOTECHNOLOGY NEWS & ANALYSIS >

Clinical Trials & Evidence

Artiva moves AlloNK cell therapy closer to phase 3 in tough rheumatoid arthritis cases

Artiva Biotherapeutics will present new ACR 2026 data showing its off-the-shelf AlloNK cell therapy, combined with rituximab, can match CAR T-like B-cell depletion in patients with hard-to-treat rheumatologic diseases.

By Elena MacLeod · October 3, 2026, 6:06 AM

Bioinformatics Methods & Tools

Clinical Trials & Evidence

CRISPR Therapeutics reveals first human data for gene-edited CAR T therapy in systemic sclerosis

October 2, 2026, 8:53 AM

AI Drug Discovery

Generate Biomedicines pushes machine learning to create new protein drugs

October 2, 2026, 7:28 AM

Biotechnology, Decoded

GenoMethods explains biotechnology from method to medicine to market, connecting scientific evidence, clinical development, companies and the technologies shaping future health.

TOP STORIES

Immix Biopharma eyes FDA filing as NXC-201 posts 89% complete response in AL amyloidosis

Anixa Biosciences records first three-month stable disease in ovarian cancer CAR-T trial

FSHR CAR T cell therapy achieves first stable disease in ovarian cancer trial

Europe’s biotechnology sector hits a wall on funding and commercialisation

Shionogi targets rare disease leadership with $2 billion IntraBio acquisition

IN-DEPTH REPORTING

Asian Biopharma Giants Reshape Global Dealmaking with Record Transactions

UNILAG opens hands-on bioinformatics workshop for faculty researchers

Oncology teams tackle relapsed CLL with CAR T trials and advanced practice teamwork

FEATURED STORIES

4D Molecular Therapeutics sets October 2026 Investor Day in New York

Novartis places $7.8 billion bet on Abogen's mRNA T cell therapy for autoimmune disease

Evident completes CrestOptics buyout to boost 3D imaging

Aroa Biosurgery Symphony speeds up diabetic foot ulcer healing in US study

Novonesis takes full control of MicroBioGen to drive yeast innovation

AstraZeneca’s $2 Billion Bet on Summit Splits the Biotech World

BIOTECHNOLOGY NEWS & ANALYSIS >

Artiva moves AlloNK cell therapy closer to phase 3 in tough rheumatoid arthritis cases

AI gene analysis uncovers circadian clock changes in chronic insomnia

Fate Therapeutics gets FDA green light for FT839 cell therapy trial in autoimmune diseases

CLINICAL TRIALS & EVIDENCE >

Novo Nordisk grabs exclusive global rights to Hengrui’s oral GLP-1 GIP drug in $2.6B deal

CRISPR Therapeutics reveals first human data for gene-edited CAR T therapy in systemic sclerosis

Generate Biomedicines pushes machine learning to create new protein drugs

Biotechnology, Decoded